Emcure Pharmaceuticals Limited (BOM:544210)

Market Cap	287.34B +9.2%
Revenue (ttm)	88.50B +17.2%
Net Income	8.70B +43.2%
EPS	45.90 +39.7%
Shares Out	n/a
PE Ratio	33.03
Forward PE	26.10
Dividend	3.00 (0.20%)
Ex-Dividend Date	Aug 14, 2025

Volume	5,211
Average Volume	12,658
Open	1,467.35
Previous Close	1,483.45
Day's Range	1,460.90 - 1,520.00
52-Week Range	890.00 - 1,585.50
Beta	n/a
RSI	53.99
Earnings Date	Feb 4, 2026

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the develop...

• Industry: Pharmaceutical Preparations
• Founded: 1981
• Employees: 6,731
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544210

Financial Performance

In fiscal year 2025, Emcure Pharmaceuticals's revenue was 78.96 billion, an increase of 18.59% compared to the previous year's 66.58 billion. Earnings were 6.81 billion, an increase of 36.76%.